Publications by authors named "F E Odicino"
The introduction of self-sampling in cervical cancer screening has raised the importance of HPV test validation on self-collected samples. This study aimed to evaluate the clinical accuracy of the OncoPredict HPV Screening (SCR) assay on self-collected vaginal and first-void urine (FVU) samples, relative to cervical specimens, using the VALHUDES Framework. FVU and vaginal self-samples followed by a clinician-collected cervical brushing were collected from 500 women referred to colposcopy and tested using OncoPredict HPV SCR assay.
View Article and Find Full Text PDFObjective: The prognostic relevance of hormonal biomarkers in endometrial cancer (EC) has been well-established. A refined three-tiered risk model for estrogen receptor (ER)/progesterone receptor (PR) expression was shown to improve prognostication. This has not been evaluated in relation to the molecular subgroups.
View Article and Find Full Text PDFArticle Synopsis
- The VALHUDES initiative aimed to evaluate the effectiveness of self-collected urine and vaginal samples for detecting cervical precancers compared to traditional clinician-collected cervical samples using the OncoPredict HPV Quantitative Typing assay.
- A study involving 490 women showed that the clinical sensitivity for detecting cervical intraepithelial neoplasia (CIN2+) was comparable between self-collected samples and cervical samples, but specificity was lower for both self-collection methods.
- After optimizing the testing criteria, the OncoPredict HPV QT assay showed similar accuracy in diagnosing cervical precancers from self-collected samples as from clinician-collected cervical samples.
Background/objectives: Endometriosis (END) is a painful gynecological condition. Clinical examination, imaging, and laparoscopy can provide a definitive diagnosis of END. Nonetheless, non-invasive biomarkers could help enhance and streamline the diagnostic process.
View Article and Find Full Text PDFArticle Synopsis
- There are currently no specific biomarkers to identify patients with advanced ovarian carcinoma who are responsive to bevacizumab (BEV), a key treatment option.
- A study analyzed TP53 mutations and p53 expression in advanced ovarian cancer patients undergoing BEV treatment, finding that unclassified missense TP53 mutations significantly improved overall survival.
- The results suggest that unclassified TP53 mutations could serve as a favorable prognostic indicator in these patients, indicating the need for further research to explore their potential role in predicting treatment outcomes.